Evaluation of Intracellular Metabolism of Methotrexate in Hepatocytes and Embryonic Kidney Cells based on Folylpolyglutamate Synthetase and Gamma-Glutamyl Hydrolase Expression
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Methotrexate (MTX) is a common folic acid antagonist in clinical medicine, easily inducing a common adverse side effect of liver and kidney injury. It has been found that the expression of Folylpolyglutamate Synthetase (FPGS) and gamma-Glutamyl Hydrolase (GGH) may be closely related to that of related proteins to affect the intracellular metabolism of MTX.
OBJECTIVE: The relationship between FPGS/GGH and MTXPGs accumulation in liver and kidney cells was explored by adjusting the expression of FPGS and GGH in cells using UPLC-MS/MS quantitative technology.
METHOD: Based on UPLC-MS/MS quantitative techniques, the relationship between MTXPGs accumulation and FPGS/GGH in hepatocytes and embryonic kidney cells was explored by adjusting the expression of FPGS and GGH, and the effect of FPGS/GGH on the intracellular toxicity of MTX was comprehensively analyzed.
RESULT: The results showed that the difference in methotrexate polyglutamates (MTXPGs) accumulation in liver and kidney cells was related to the difference in FPGS and GGH expression. The expression of FPGS interacted with that of GGH. These results suggest that the protein abundance ratio of FPGS to GGH (FPGS/GGH) has more potential to be used as a predictor of MTX efficacy than the FPGS or GGH single protein index. This can effectively avoid liver and kidney damage caused by MTX and guides the rational use of drugs in MTX.
CONCLUSION: The results prove that there is a positive correlation between the FPGS/GGH and the accumulation of MTXPGS in liver and kidney cells. Summarily, the FPGS/GGH is expected to be a predictor for MTXPGs accumulation and provides an effective method to evaluate the toxicity caused by MTX.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current drug metabolism - 24(2023), 2 vom: 06., Seite 139-147 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Hanbing [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.06.2023 Date Revised 01.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389200224666230406120714 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355432323 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355432323 | ||
| 003 | DE-627 | ||
| 005 | 20231226064331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389200224666230406120714 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355432323 | ||
| 035 | |a (NLM)37038713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Hanbing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Intracellular Metabolism of Methotrexate in Hepatocytes and Embryonic Kidney Cells based on Folylpolyglutamate Synthetase and Gamma-Glutamyl Hydrolase Expression |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2023 | ||
| 500 | |a Date Revised 01.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Methotrexate (MTX) is a common folic acid antagonist in clinical medicine, easily inducing a common adverse side effect of liver and kidney injury. It has been found that the expression of Folylpolyglutamate Synthetase (FPGS) and gamma-Glutamyl Hydrolase (GGH) may be closely related to that of related proteins to affect the intracellular metabolism of MTX | ||
| 520 | |a OBJECTIVE: The relationship between FPGS/GGH and MTXPGs accumulation in liver and kidney cells was explored by adjusting the expression of FPGS and GGH in cells using UPLC-MS/MS quantitative technology | ||
| 520 | |a METHOD: Based on UPLC-MS/MS quantitative techniques, the relationship between MTXPGs accumulation and FPGS/GGH in hepatocytes and embryonic kidney cells was explored by adjusting the expression of FPGS and GGH, and the effect of FPGS/GGH on the intracellular toxicity of MTX was comprehensively analyzed | ||
| 520 | |a RESULT: The results showed that the difference in methotrexate polyglutamates (MTXPGs) accumulation in liver and kidney cells was related to the difference in FPGS and GGH expression. The expression of FPGS interacted with that of GGH. These results suggest that the protein abundance ratio of FPGS to GGH (FPGS/GGH) has more potential to be used as a predictor of MTX efficacy than the FPGS or GGH single protein index. This can effectively avoid liver and kidney damage caused by MTX and guides the rational use of drugs in MTX | ||
| 520 | |a CONCLUSION: The results prove that there is a positive correlation between the FPGS/GGH and the accumulation of MTXPGS in liver and kidney cells. Summarily, the FPGS/GGH is expected to be a predictor for MTXPGs accumulation and provides an effective method to evaluate the toxicity caused by MTX | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MTXPGs accumulation | |
| 650 | 4 | |a Methotrexate | |
| 650 | 4 | |a cell pharmacokinetics | |
| 650 | 4 | |a folylpolyglutamate synthetase | |
| 650 | 4 | |a gamma-glutamyl hydrolase | |
| 650 | 4 | |a hepatocytes and embryonic kidney cells | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a folylpolyglutamate synthetase |2 NLM | |
| 650 | 7 | |a EC 6.3.2.17 |2 NLM | |
| 650 | 7 | |a gamma-Glutamyl Hydrolase |2 NLM | |
| 650 | 7 | |a EC 3.4.19.9 |2 NLM | |
| 700 | 1 | |a Yang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yucui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Huanhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Tongji |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Zhonghua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug metabolism |d 2000 |g 24(2023), 2 vom: 06., Seite 139-147 |w (DE-627)NLM113669038 |x 1875-5453 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:2 |g day:06 |g pages:139-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389200224666230406120714 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 2 |b 06 |h 139-147 | ||